Moderna to Host Science Day on May 7, 2019 and Report First Quarter Financial Results on May 8, 2019
April 16 2019 - 08:00AM
Business Wire
Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology
company pioneering messenger RNA (mRNA) therapeutics and vaccines
to create a new generation of transformative medicines for
patients, today announced that it will host its annual Science
Day for analysts and investors on Tuesday, May 7, 2019 at 8:00 a.m.
ET in Cambridge, MA. Moderna also announced that it will report its
first quarter 2019 financial results before the market opens on
Wednesday, May 8, 2019 and, subsequently, host a conference call to
discuss these results and provide a corporate update.
Science Day:
Moderna’s Science Day will feature presentations from Stephen
Hoge M.D., president and Melissa Moore Ph.D., chief scientific
officer of Moderna’s mRNA Research Platform with a focus on the
Company’s newest advances from its commitment to basic and applied
sciences. Moderna will also host a tour of the Norwood
manufacturing facility in the afternoon.
First Quarter 2019 Financial Results:
Moderna’s first quarter 2019 financial results and corporate
update conference call will begin at 8:00 a.m. ET on May 8, 2019.
To access the live conference call, please dial 866-922-5184
(domestic) or 409-937-8950 (international), and refer to conference
ID 8273939.
Both events will be webcast live under “Events &
Presentations” in the Investors section of the Moderna website at
https://investors.modernatx.com/. The archived webcasts will be
available on Moderna’s website approximately two hours after each
event and will be available for 30 days following the events.
About Moderna
Moderna is advancing messenger RNA (mRNA) science to create
a new class of transformative medicines for patients. mRNA
medicines are designed to direct the body’s cells to produce
intracellular, membrane or secreted proteins that have a
therapeutic or preventive benefit with the potential to address a
broad spectrum of diseases. Moderna’s platform builds on continuous
advances in basic and applied mRNA science, delivery technology and
manufacturing, providing the Company the capability to pursue in
parallel a robust pipeline of new development
candidates. Moderna is developing therapeutics and
vaccines for infectious diseases, immuno-oncology, rare diseases
and cardiovascular diseases, independently and with strategic
collaborators.
Headquartered in Cambridge,
Mass., Moderna currently has strategic alliances for
development programs with AstraZeneca, Plc. and Merck,
Inc., as well as the Defense Advanced Research Projects
Agency (DARPA), an agency of the U.S. Department of
Defense and the Biomedical Advanced Research and
Development Authority (BARDA), a division of the Office
of the Assistant Secretary for Preparedness and
Response (ASPR) within the U.S. Department of Health and
Human Services (HHS). Moderna has been ranked in the
top ten of Science’s list of top biopharma industry
employers for the past four years. To learn more,
visit www.modernatx.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190416005246/en/
Moderna Contacts:Investors:Lavina TalukdarHead,
Investor Relations617-209-5834Lavina.talukdar@modernatx.com
Media:Jason GlashowHead, Corporate
Communications617-674-5648Jason.glashow@modernatx.com
Moderna (NASDAQ:MRNA)
Historical Stock Chart
From Feb 2024 to Mar 2024
Moderna (NASDAQ:MRNA)
Historical Stock Chart
From Mar 2023 to Mar 2024